Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Cancer. 2018 Dec 19;125(3):374–381. doi: 10.1002/cncr.31910

Table 1.

Baseline demographic characteristics by residence in states subject to parity laws and those not subject to them.

Total
Non-Parity States
Parity States
 
Patient Characteristics No.a No.a (%) No.a (%) Pb
Total 7778 6172 (100.0) 1606 (100.0)
Oral endocrine therapy 0.096
  Anastrozole 2392 1930 (31.3) 462 (28.8)
  Exemestane 805 651 (10.5) 154 (9.6)
  Letrozole 1454 1142 (18.5) 312 (19.4)
  Tamoxifen 3127 2449 (39.7) 678 (42.2)
Year of index claim <0.001
  2007–2008 1782 1748 (28.3) 34 (2.1)
  2009–2010 1836 1415 (22.9) 421 (26.2)
  2011–2012 2312 1558 (25.2) 754 (46.9)
  2013–2015 1848 1451 (23.5) 397 (24.7)
Age, years 0.335
  18–44 1017 806 (13.1) 211 (13.1)
  45–54 3266 2562 (41.5) 704 (43.8)
  55–59 1842 1474 (23.9) 368 (22.9)
  60–64 1653 1330 (21.5) 323 (20.1)
Charlson-Deyo
comorbidity score
0.366
  0 7096 5641 (91.4) 1455 (90.6)
  1 573 450 (7.3) 123 (7.7)
  2 or higher 109 81 (1.3) 28 (1.7)
Diagnosis 0.853
  Invasive cancer 6950 5517 (89.4) 1433 (89.2)
  Carcinoma in-situ 828 655 (10.6) 173 (10.8)
Geographic region <0.001
  Northeast 349 179 (2.9) 170 (10.6)
  Midwest 2614 2158 (35.0) 456 (28.4)
  South 2215 1464 (23.7) 751 (46.8)
  West 2600 2371 (38.4) 229 (14.3)
Insurance plan type <0.001
  HMO 2269 1864 (30.2) 405 (25.2)
  POS 5121 4060 (65.8) 1061 (66.1)
  Otherc 388 248 (4.0) 140 (8.7)  
a

Number of unique drug therapy courses, defined as single drug type per patient. Patients may have had multiple (up to 4) drug therapy courses.

b

Pearson’s chi-squared p value

c

Includes preferred provider organization, exclusive provider organization, and indemnity plans

Abbreviations: HMO (health maintenance organization); POS (point of service)